Melatonin Replacement for Treatment of Sleep Disruption

The purpose of this study is to determine if replacing melatonin function with a melatonin agonist (ramelteon) in individuals that lack endogenous melatonin production (tetraplegia) helps to alleviate self-reported sleep disruption.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : Placebo
  • drug : ramelteon

Phase: Phase 4


Ages Eligible For Study:

18 Years - 65 Years

Inclusion Criteria

- Age 18 years or older, male or female veterans of any racial or ethnic group - Neurologically complete (Frankel A or B) damage to the lower (C4-C8) cervical spinal cord - Absence of melatonin production - Time since SCI is greater than 6 months [no cases of acute spinal cord injury] - Subjective complaint of sleep disruption

External Links

Contact information

Primary Contact:

Ban Ku 6508491971

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: